Virax Biolabs Group (VRAX) FDA Approvals $3.04 -0.07 (-2.25%) Closing price 04:00 PM EasternExtended Trading$3.08 +0.04 (+1.35%) As of 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsTrendsBuy This Stock Virax Biolabs Group's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Virax Biolabs Group (VRAX). Over the past two years, Virax Biolabs Group has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as ViraxImmune. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. ViraxImmune FDA Regulatory Events ViraxImmune is a drug developed by Virax Biolabs Group for the following indication: Long COVID and Related Post-Acute Infection Syndromes. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Positive Data - May 26,2026Positive Data Drug: ViraxImmuneAnnounced Date: May 26, 2026Indication: Long COVID and Related Post-Acute Infection SyndromesAnnouncementVirax Biolabs Group Limited today reported positive early pilot performance data for ViraxImmune™, its blood-based test in development for Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome ("ME/CFS") and related post-acute infection syndromes ("PAIS").AI SummaryVirax Biolabs Group Limited said early pilot data for ViraxImmune™, its blood-based test under development for Long COVID, ME/CFS, and related post-acute infection syndromes, showed positive signs. The company said the results are from the VRX003 study and are still very early, so they should be seen as preliminary. Virax said the findings will help guide ongoing test development and plans for future clinical validation. ViraxImmune™ is not approved for diagnostic use in any country. The company is working on T cell-based testing tools that may help measure immune responses and support a broader immunology profiling platform. Virax said these types of tests could have uses in conditions tied to immune system problems, including Long COVID and other chronic illnesses.Read Announcement Virax Biolabs Group FDA Events - Frequently Asked Questions Has Virax Biolabs Group received FDA approval? As of now, Virax Biolabs Group (VRAX) has not received any FDA approvals for its therapy in the last two years. What drugs has Virax Biolabs Group submitted to the FDA? In the past two years, Virax Biolabs Group (VRAX) has reported FDA regulatory activity for ViraxImmune. What is the most recent FDA event for Virax Biolabs Group? The most recent FDA-related event for Virax Biolabs Group occurred on May 26, 2026, involving ViraxImmune. The update was categorized as "Positive Data," with the company reporting: "Virax Biolabs Group Limited today reported positive early pilot performance data for ViraxImmune™, its blood-based test in development for Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome ("ME/CFS") and related post-acute infection syndromes ("PAIS")." What conditions do Virax Biolabs Group's current drugs treat? Currently, Virax Biolabs Group has one therapy (ViraxImmune) targeting the following condition: Long COVID and Related Post-Acute Infection Syndromes. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Agios Pharmaceuticals FDA EventsAlterity Therapeutics FDA EventsAxsome Therapeutics FDA EventsCompass Pathways FDA EventsErnexa Therapeutics FDA EventsKymera Therapeutics FDA EventsSAB Biotherapeutics FDA EventsTurn Therapeutics FDA EventsTvardi Therapeutics FDA EventsAgenus FDA EventsAtai Beckley FDA EventsFate Therapeutics FDA EventsGenmab A/S FDA EventsImmuron FDA EventsIonis Pharmaceuticals FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies CASI Pharmaceuticals FDA Events Purple Biotech FDA Events Jaguar Animal Health FDA Events PMGC FDA Events Abpro FDA Events PainReform FDA Events Silexion Therapeutics FDA Events Scinai Immunotherapeutics FDA Events Windtree Therapeutics FDA Events ProPhase Labs FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:VRAX last updated on 5/26/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Positive Data - May 26,2026Positive Data Drug: ViraxImmuneAnnounced Date: May 26, 2026Indication: Long COVID and Related Post-Acute Infection SyndromesAnnouncementVirax Biolabs Group Limited today reported positive early pilot performance data for ViraxImmune™, its blood-based test in development for Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome ("ME/CFS") and related post-acute infection syndromes ("PAIS").AI SummaryVirax Biolabs Group Limited said early pilot data for ViraxImmune™, its blood-based test under development for Long COVID, ME/CFS, and related post-acute infection syndromes, showed positive signs. The company said the results are from the VRX003 study and are still very early, so they should be seen as preliminary. Virax said the findings will help guide ongoing test development and plans for future clinical validation. ViraxImmune™ is not approved for diagnostic use in any country. The company is working on T cell-based testing tools that may help measure immune responses and support a broader immunology profiling platform. Virax said these types of tests could have uses in conditions tied to immune system problems, including Long COVID and other chronic illnesses.Read Announcement
